Defensin-6

Also known as: Defensin, alpha 6, DEFA6, Q01524

**Mechanism of Action** Defensin-6 (DEFA6) is a host-defense peptide expressed primarily in Paneth cells of the small intestine. It exerts antimicrobial activity through the formation of higher-order oligomers (nanonets) that physically entrap bacteria, preventing microbial adhesion and invasion of the intestinal epithelium. This mechanism is distinct from membrane disruption, relying instead on self-assembly into fibrillar structures that immobilize pathogens and maintain mucosal barrier integrity. DEFA6 also modulates innate immune signaling, though its direct bactericidal effects are limited compared to other alpha-defensins. **Key Research Findings** Preclinical studies demonstrate that DEFA6 oligomerization is calcium-dependent and requires specific disulfide bonding patterns for structural stability. In murine models, DEFA6 deficiency leads to increased bacterial translocation and susceptibility to enteric infections, highlighting its role in gut homeostasis. Human studies show reduced DEFA6 expression in inflammatory bowel disease (IBD), particularly Crohn’s disease, correlating with impaired antimicrobial defense. Experimental evidence also suggests DEFA6 interacts with the gut microbiome, selectively targeting Gram-negative bacteria while sparing commensals. **Clinical Relevance** DEFA6 is under investigation as a biomarker for intestinal barrier dysfunction and as a therapeutic target for IBD and infectious colitis. Its ability to form nanonets offers a novel approach to antimicrobial therapy, potentially reducing reliance on broad-spectrum antibiotics. However, clinical applications remain experimental, with no approved therapies to date. Further research is needed to elucidate its role in chronic inflammation and to develop stable peptide analogs for clinical use. For research purposes only — not medical advice.

Key data

Mechanism of action

Host-defense peptide that contributes to intestinal innate immunity and mediates homeostasis at mucosal surfaces by forming higher-order oligomers that capture bacteria and prevent microbial invasion of the epithelium (PubMed:15616305, PubMed:17088326, PubMed:25158166, PubMed:25354318, PubMed:28026958). After binding to bacterial surface proteins, undergoes ordered self-assembly to form fibril-like nanonets that surround and entangle bacteria and thereby prevent bacterial invasion across the epithelial barrier (PubMed:22722251). Entangles and agglutinates Gram-negative bacteria, such as E.coli, S.typhimurium and Y.enterocolitica, and Gram-positive bacteria such as L.monocytogenes, thereby protecting the intestine against invasion by enteric bacterial pathogens (PubMed:22722251, PubMed:25158166, PubMed:27076903). Blocks adhesion of C.albicans to intestinal epithelial cells and thereby suppresses fungal invasion of epithelial cells and biofilm formation (PubMed:28026958). Under reducing conditions and in an acidic environment similar to the intestinal milieu, exhibits inhibitory activity against anaerobic bacteria such as B.adolescentis, L.acidophilus and B.breve, as well as B.longum and S.thermophilus, possibly by leading to alterations in bacterial cell envelope structures (PubMed:25354318). The disulfide-linked oxidized form exhibits negligible antimicrobial activity against Gram-negative and Gram-positive bacteria, as compared to the enteric defensin DEFA5 (PubMed:15616305, PubMed:17088326)

Research & studies

Frequently asked questions

Related peptides